Spots Global Cancer Trial Database for Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer

Official Title: Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Patients With Metastatic Breast Cancer. A Multicenter Phase II Study

Study ID: NCT00694200

Conditions

Breast Cancer

Interventions

Vinorelbine

Bevacizumab

Study Description

Brief Summary: To evaluate the efficacy of metronomic oral vinorelbine taken three times a week without break plus bevacizumab as salvage treatment in patients with metastatic breast cancer.

Detailed Description: Continuous administration of oral vinorelbine, given three times a week (metronomic) is feasible and exceptionally well tolerated at doses up to 50 mg. Early results show activity against refractory tumors and provide evidence towards clinical proof of efficacy for metronomic chemotherapy. Recently, initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab demonstrated prolonged progression-free survival, as compared with paclitaxel alone.